Celldex Therapeutics, Inc.
Company Stats
- Market Cap
- $2.5B
- as of Sep 30, 2026
- Shares Outstanding
- 78.5M
- Free Float
- 92.4%
Income Statement
- Revenue
- $1.5M
- Operating Income
- -$287.4M
- Net Income
- -$258.8M
- EBITDA
- -$284.0M
- Revenue Growth, 3Y
- -13.1%
- FCF Margin, 3Y Avg
- -5896.4%
- FCF Margin, Worst Year
- -13829.1%
Cash Flow
- Free Cash Flow
- -$213.7M
- FCF Yield
- -8.4%
- Owner FCF Yield
- -9.8%
Balance Sheet
- Cash & Equivalents
- $28.9M
Returns & Capital
- SBC, 3Y Avg
- $31.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.5M | -$213.7M | -13829.1% |
| FY2024 | $7.0M | -$159.7M | -2274.9% |
| FY2023 | $6.9M | -$109.1M | -1585.2% |
| FY2022 | $2.4M | -$105.6M | -4478.6% |
| FY2021 | $4.7M | -$62.2M | -1336.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Utilities Lead Quarterly Dilution as Materials Buybacks Gain